Helmholtz Gemeinschaft


PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
[img] Other (Supplementary Information)

Item Type:Article
Title:PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma
Creators Name:Garces de Los Fayos Alonso, I. and Zujo, L. and Wiest, I. and Kodajova, P. and Timelthaler, G. and Edtmayer, S. and Zrimšek, M. and Kollmann, S. and Giordano, C. and Kothmayer, M. and Neubauer, H.A. and Dey, S. and Schlederer, M. and Schmalzbauer, B.S. and Limberger, T. and Probst, C. and Pusch, O. and Högler, S. and Tangermann, S. and Merkel, O. and Schiefer, A.I. and Kornauth, C. and Prutsch, N. and Zimmerman, M. and Abraham, B. and Anagnostopoulos, J. and Quintanilla-Martinez, L. and Mathas, S. and Wolf, P. and Stoiber, D. and Staber, P.B. and Egger, G. and Klapper, W. and Woessmann, W. and Look, T.A. and Gunning, P. and Turner, S.D. and Moriggl, R. and Lagger, S. and Kenner, L.
Abstract:BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptionally regulate PDGFRβ. Blocking PDGFRβ kinase activity with imatinib effectively reduces tumor burden and prolongs survival, although the downstream molecular mechanisms remain elusive. METHODS AND RESULTS: In a transgenic mouse model that mimics PDGFRβ-driven human ALCL in vivo, we identify PDGFRβ as a driver of aggressive tumor growth. Mechanistically, PDGFRβ induces the pro-survival factor Bcl-x(L) and the growth-enhancing cytokine IL-10 via STAT5 activation. CRISPR/Cas9 deletion of both STAT5 gene products, STAT5A and STAT5B, results in the significant impairment of cell viability compared to deletion of STAT5A, STAT5B or STAT3 alone. Moreover, combined blockade of STAT3/5 activity with a selective SH2 domain inhibitor, AC-4-130, effectively obstructs tumor development in vivo. CONCLUSIONS: We therefore propose PDGFRβ as a novel biomarker and introduce PDGFRβ-STAT3/5 signaling as an important axis in aggressive ALCL. Furthermore, we suggest that inhibition of PDGFRβ or STAT3/5 improve existing therapies for both previously untreated and relapsed/refractory ALK(+) ALCL patients.
Keywords:ALCL, PDGFRß, STAT3, STAT5A, STAT5B, NPM-ALK, Apoptosis, Animals, Mice
Source:Molecular Cancer
Publisher:BioMed Central
Page Range:172
Date:31 August 2022
Official Publication:https://doi.org/10.1186/s12943-022-01640-7
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library